Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 62 for:    Baricitinib

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04088396
Recruitment Status : Not yet recruiting
First Posted : September 12, 2019
Last Update Posted : December 3, 2019
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA).

Condition or disease Intervention/treatment Phase
Systemic Juvenile Idiopathic Arthritis Drug: Baricitinib Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 103 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis
Estimated Study Start Date : January 1, 2020
Estimated Primary Completion Date : April 7, 2023
Estimated Study Completion Date : April 7, 2023


Arm Intervention/treatment
Experimental: Baricitinib
Baricitinib given orally.
Drug: Baricitinib
Administered orally
Other Name: LY3009104

Placebo Comparator: Placebo
Placebo given orally.
Drug: Placebo
Administered orally




Primary Outcome Measures :
  1. Time to Disease Flare [ Time Frame: Week 24 to End of Double Blind Withdrawal (DBW) Period (Disease Flare or up to Week 56) ]
    Time to Disease Flare


Secondary Outcome Measures :
  1. Percentage of Participants Achieving Pediatric American College of Rheumatology 30 Responder Index (PedACR30) [ Time Frame: Baseline through End of DBW Period (Disease Flare or up to Week 56) ]
    Percentage of Participants Achieving PedACR30

  2. Percentage of Participants with Inactive Disease [ Time Frame: Baseline through End of DBW Period (Disease Flare or up to Week 56) ]
    Percentage of Participants with Inactive Disease

  3. Percentage of Participants with Minimal Disease Activity [ Time Frame: Baseline through End of DBW Period (Disease Flare or up to Week 56) ]
    Percentage of Participants with Minimal Disease Activity

  4. Percentage of Participants in Remission [ Time Frame: Baseline through End of DBW Period (Disease Flare or up to Week 56) ]
    Percentage of Participants in Remission

  5. Change from Baseline in Juvenile Arthritis Disease Activity Score (JADAS)-27 [ Time Frame: Baseline, End of DBW Period (Disease Flare or up to Week 56) ]
    Change from Baseline in JADAS-27

  6. Change from Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item [ Time Frame: Baseline, End of DBW Period (Disease Flare or up to Week 56) ]
    Change from Baseline in Arthritis-Related Pain Severity as Measured by the CHAQ Pain VAS Item

  7. Pharmacokinetics (PK): Maximum Plasma Baricitinib Concentration at Steady-State (Cmax, ss) [ Time Frame: Baseline through End of DBW Period (Disease Flare or up to Week 56) ]
    PK: Cmax, ss of Baricitinib

  8. PK: Area Under the Baricitinib Concentration-Time Curve at Steady-State (AUC, ss) [ Time Frame: Baseline through End of DBW Period (Disease Flare or up to Week 56) ]
    PK: AUC, ss of Baricitinib



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants must have a diagnosis of systemic Juvenile Idiopathic Arthritis (sJIA) as defined by International League of Associations for Rheumatology (ILAR) criteria with onset before the age of 16 years.
  • Participants must have arthritis in 1 or more joints with or preceded by fever of at least 2 weeks' duration that is documented to be daily (quotidian) fever for at least 3 days, and accompanied by 1 or more of the following:

    • Evanescent (nonfixed) erythematous rash
    • Generalized lymph node enlargement
    • Hepatomegaly and/or splenomegaly
    • Serositis
  • Participants must have at least 2 active joints at screening and baseline.

Exclusion Criteria:

  • Participants must not have polyarticular JIA (positive or negative for rheumatoid factor), extended oligoarticular JIA, enthesitis-related JIA, or juvenile psoriatic arthritis.
  • Participants must not have persistent oligoarticular arthritis as defined by the ILAR criteria.
  • Participants must not have a history or presence of any autoimmune inflammatory condition other than JIA, such as Crohn's disease or ulcerative colitis.
  • Participants must not have active anterior uveitis or are receiving concurrent treatment for anterior uveitis.
  • Participants must not have active fibromyalgia or other chronic pain conditions that, in the investigator's opinion, would make it difficult to appropriately assess disease activity for the purposes of this study.
  • Participants must not have biologic features of Macrophage Activation Syndrome (MAS).
  • Participants must not have a current or recent (<4 weeks prior to baseline) clinically serious infection.
  • Participants must not have a positive test for hepatitis B virus.
  • Participants must not have evidence of active tuberculosis (TB) or untreated latent TB.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04088396


Contacts
Layout table for location contacts
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 ClinicalTrials.gov@lilly.com

  Show 73 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Additional Information:
Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT04088396     History of Changes
Other Study ID Numbers: 16275
I4V-MC-JAHU ( Other Identifier: Eli Lilly and Company )
2017-004495-60 ( EudraCT Number )
First Posted: September 12, 2019    Key Record Dates
Last Update Posted: December 3, 2019
Last Verified: December 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
URL: http://www.vivli.org/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eli Lilly and Company:
Systemic
Fever
Flare
sJIA
JIA
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Juvenile
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases